當前國內(nèi)新型冠狀病毒肆虐，嚴重危害人們健康。新型冠狀病毒感染性強，感染后的重型患者病死率高，尚無有效治療方法。間充質(zhì)干細胞具有強大的抗炎和免疫調(diào)節(jié)功能，通過抑制肺部浸潤的免疫細胞減輕急慢性肺損傷，并降低炎性因子分泌水平，降低細胞因子風暴和急性呼吸窘迫綜合征發(fā)生的風險，有望降低患者的死亡率；同時間充質(zhì)干細胞具有降低肺部纖維化水平、增強組織損傷修復的能力，是治療難治性肺損傷相關(guān)疾病的一種具有良好臨床前景的選擇。結(jié)合臨床前及臨床研究的有關(guān)進展，對間充質(zhì)干細胞治療新型冠狀病毒肺炎進行有效性評價。

At present, China is the focus of global attention due to an outbreak of a febrile respiratory illness due to a new novel coronavirus SARS-COV-2, which seriously endangers people's health. The new type of coronavirus is highly infectious, and the mortality of severe patients with the novel coronavirus pneumonia is high. However, there is no effective treatment method. It is urgent to find a safe and effective treatment. Studies have found that mesenchymal stem cells have powerful anti-inflammatory and immunoregulatory functions. They can reduce acute and chronic lung injury by suppressing lung infiltrating immune cells, and reduce the secretion of inflammatory factors. At the same time, MSCs can reduce the lung fibrosis level and could markedly improve the degree of lung ability. It is a promising treatment option of refractory lung injury-related diseases with mesenchymal stem cells. This article reviews preclinical and clinical research and evaluate the effectiveness of mesenchymal stem cells in the treatment of novel coronavirus pneumonia.

R329